Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.
Caio Max S. Rocha Lima, Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Patrick J. Roberts(Argos Therapeutics (United States)), Petros Nikolinakos(University Cancer and Blood Center), Geoffrey I. Shapiro(Brigham and Women's Hospital), John Hamm(Ontario Institute for Cancer Research), Konstantin H. Dragnev(Dartmouth Cancer Center), Victor Priego(Center for Cancer and Blood Disorders), Steven R. Schuster(University of Colorado Hospital), Katie Stabler(Triangle), Maen Hussein(Sarah Cannon), Melanie B. Thomas(The University of Texas Southwestern Medical Center), Elizabeth Andrews(University of California, Irvine), Vi K. Chiu(University of New Mexico), Raid Aljumaily(Sarah Cannon), Stephen G. Divers, Ralph V. Boccia(Center for Cancer and Blood Disorders), Rajesh Malik(Agennix (United States)), Robert J. Hoyer(Georgetown University), Donald Richards(The US Oncology Network)
Cited by 9
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k